The Approval Granted By The Us Food And Drug Administration (Usfda) Is For Minocycline Hydrochloride Extended-Release Tablets Of Strengths 55 Mg, 65 Mg, And 115 Mg, Zydus Lifesciences Said In A Regulatory Filing.The Product Will Be Manufactured At The Group'S Formulation Manufacturing Facility In Moraiya, Ahmedabad, Zydus Lifesciences Said. (Representative Image)Zydus Lifesciences On Monday Said It Has Received Final Approval From The Us Health Regulator For Its Generic Antibiotic Minocycline Hydrochloride Extended-Release Tablets Used For Treatment Of Moderate To Severe Acne.The Approval Granted By The Us Food And Drug Administration (Usfda) Is For Minocycline Hydrochloride Extended-Release Tablets Of Strengths 55 Mg, 65 Mg, And 115 Mg, Zydus Lifesciences Said In A Regulatory Filing.The Tablet Is Used For Treatment Of Moderate To Severe Acne In People Aged 12 Years And Above.The Product Will Be Manufactured At The Group'S Formulation Manufacturing Facility In Moraiya, Ahmedabad, The Company Said.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!